Michael B Jordan MD
Associate Professor, Pediatrics, University of Cincinnati College of Medicine
Join to View Full Profile
3333 Burnet Ave# ML5021Cincinnati, OH 45229
Phone+1 513-636-9985
Fax+1 866-213-7089
Dr. Jordan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Pediatric Hematology/Oncology, 1996 - 2002
University of Texas Southwestern Medical CenterResidency, Pediatrics, 1993 - 1996
University of Texas Southwestern Medical SchoolClass of 1993
Certifications & Licensure
OH State Medical License 2004 - 2026
CO State Medical License 1996 - 2009
TX State Medical License 1995 - 1997
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Start of enrollment: 2010 Apr 01
- Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis Start of enrollment: 2013 Jul 01
- A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody Start of enrollment: 2014 Aug 04
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsMalignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome.Adi Zoref-Lorenz, Thomas E Witzig, James R Cerhan, Michael B Jordan
Leukemia & Lymphoma. 2025-04-01 - 1 citationsEmapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review St...Shanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, John Carter, May Chien
Arthritis & Rheumatology. 2025-02-01 - PRMT5 Inhibition Reduces Hyperinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis (HLH).Fiona Brown-Burke, Rachel Saadey, Hsiao-Yin Charlene Charlene Mao, Paola Marra, Eric Brooks
Blood Advances. 2025-01-18
Journal Articles
- Review and Feature Article Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the...Michael Jordan, MD, ScienceDirect
- Extending Remission and Reversing New Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T CellsMichael B Jordan, Jonathan D Katz, Diabetes Care
Grant Support
- Hybrid Immunotherapy (Atg/Dexamethasone/Etoposide) For Hemophagocytic LymphohistiNational Heart, Lung, And Blood Institute2012
- An Animal Model Of Hemophagocytic LymphohistiocytosisNational Heart, Lung, And Blood Institute2010–2011
- An Animal Model Of Hemophagocytic LymphohistiocytosisNational Heart, Lung, And Blood Institute2007–2009
- B Cell Expansion After Dendritic Cell ImmunizationNational Institute Of Allergy And Infectious Diseases2004
- B Cell Expansion After Dendritic Cell ImmunizationNational Institute Of Allergy And Infectious Diseases2002–2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
